# EDGAR Filing Document

**Accession Number:** 0001402328
**File Stem:** 0001683168-25-009103
**Filing Date:** 2025-12
**Character Count:** 6208
**Document Hash:** 0b32ab095637fa5b086e590c5613ea27
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-009103.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001683168-25-009103

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251211

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sunshine Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001402328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205566275
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41282
- **FILM NUMBER:** 251568075

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-330-0684

**MAIL ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sunshine Biopharma, Inc
- **DATE OF NAME CHANGE:** 20091102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mountain West Business Solutions, Inc
- **DATE OF NAME CHANGE:** 20071030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** mountain west business solutions,inc
- **DATE OF NAME CHANGE:** 20070607

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **<u>December 11, 2025</u>**

**<u>SUNSHINE BIOPHARMA INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Colorado</u>** | **<u>001-41282</u>** | **<u>20-5566275</u>** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer ID No.) |

---

**333 Las Olas Way**

**CU4 Suite 433**

**<u>Fort Lauderdale</u>** **<u>, FL</u> <u>33301</u>**

(Address of principal executive offices) (zip code)

**<u>(954) 330-0684</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| Common Stock, par value $0.001 | SBFM | The Nasdaq Stock Market LLC |
| Common Stock Purchase Warrants | SBFMW | The Nasdaq Stock Market LLC |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On December 11, 2025, Sunshine Biopharma Inc. (the "Company") held its annual meeting of stockholders. At the meeting, (i) Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified, (ii) stockholders ratified the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for 2025, and (iii) stockholders approved an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 683,000.

The vote on these matters was as follows:

(i) Election of Directors:

---

| | | | |
|:---|:---|:---|:---|
|  | <u>FOR</u> | <u>WITHHELD</u> | <u>BROKER NON-VOTE</u> |
| Dr. Steve N. Slilaty | 130382043 | 58298 | 1774854 |
| Mr. Camille Sebaaly | 130382204 | 58137 | 1774854 |
| Dr. Rabi Kiderchah | 130383638 | 56703 | 1774854 |
| Mr. David Natan | 130382135 | 58206 | 1774854 |
| Dr. Andrew Keller | 130383893 | 56448 | 1774854 |

---

(ii) Ratification of the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for 2025.

---

| | | | |
|:---|:---|:---|:---|
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE |
| 132026819 | 177963 | 10413 | <u>0</u> |

---

(iii) Approval of an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 683,000.

---

| | | | |
|:---|:---|:---|:---|
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE |
| 130139733 | 293771 | 6837 | 1774854 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: December 12, 2025 | **SUNSHINE BIOPHARMA INC.** |
|  | By: <u>/s/ Dr. Steve N. Slilaty&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Dr. Steve N. Slilaty, Chief Executive Officer |

---